Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. [electronic resource]
Producer: 20210128Description: 120 p. digitalISSN:- 1471-230X
- Anilides -- economics
- Antineoplastic Agents -- economics
- Carcinoma, Hepatocellular -- drug therapy
- Cost-Benefit Analysis
- Drug Resistance, Neoplasm
- Germany
- Humans
- Liver Neoplasms -- drug therapy
- Markov Chains
- Pyridines -- economics
- Quality-Adjusted Life Years
- Sorafenib -- therapeutic use
- Survival Analysis
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.